IDH2 and central nervous system cancer: Another ongoing clinical trial is being conducted on IDH1 or IDH2 mutation-bearing adult glioma patients to test if nivolumab (anti- PD-1 antibody) stops tumor growth and provides long-lasting control of the tumor.